Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma

Yidan Xia¹, Dongxu Wang²†, Yuting Piao³, Minqi Chen¹, Duo Wang¹, Ziping Jiang⁴* and Bin Liu¹*

¹Department of Hand and Foot Surgery, The First Hospital of Jilin University, Changchun, China,
²Laboratory Animal Center, College of Animal Science, Jilin University, Changchun, China

The most common bone cancer is osteosarcoma (OS), which mostly affects children and teenagers. Early surgical resection combined with chemotherapy significantly improves the prognosis of patients with OS. Existing chemotherapies have poor efficacy in individuals with distant metastases or inoperable resection, and these patients may respond better to novel immunotherapies. Immune escape, which is mediated by immunosuppressive cells in the tumour microenvironment (TME), is a major cause of poor OS prognosis and a primary target of immunotherapy. Myeloid-derived suppressor cells, regulatory T cells, and tumour-associated macrophages are the main immunosuppressor cells, which can regulate tumorigenesis and growth on a variety of levels through the interaction in the TME. The proliferation, migration, invasion, and epithelial–mesenchymal transition of OS cells can all be impacted by the expression of non-coding RNAs (ncRNAs), which can also influence how immunosuppressive cells work and support immune suppression in TME. Interferon, checkpoint inhibitors, cancer vaccines, and engineered chimeric antigen receptor (CAR-T) T cells for OS have all been developed using information from studies on the metabolic properties of immunosuppressive cells in the tumour microenvironment (TME), and more. This review summarizes the regulatory effect of ncRNAs on OS cells as well as the metabolic heterogeneity of immunosuppressive cells in the context of OS immunotherapies.

KEYWORDS
osteosarcoma, noncoding RNA, immunosuppressive cells, TME, immunotherapy, metabolic heterogeneity
Introduction

Osteosarcoma (OS) is a malignant mesenchymal tumour that most commonly affects children and adolescents and has a high rate of metastasis and mortality (1). OS primarily affects the epiphysis of the long bones in the extremities, with lung metastases occurring most frequently (2). Current treatments for OS include surgical resection and adjuvant chemotherapy, which typically result in a survival rate of less than 5 years for patients with distant metastases (3). Metastatic OS has been successfully treated with immunotherapy, and the mechanisms underlying this success are related to the heterogeneity of immunosuppressive cells in metastatic tumours and the interaction of stromal and immunosuppressive cells in the tumour microenvironment (TME) (4).

The TME in OS is complex and diverse and plays a critical role in tumorigenesis and development. The TME consists of stromal cells and other key factors, including cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix, and vasculature (5). To promote the occurrence and development of tumour cells, stromal cells secrete cytokines, growth factors, and chemokines (6). Immune cells such as lymphocytes and natural killer cells can effectively control tumour invasion, which can be suppressed by immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and tumour-associated macrophages (TAMs) (7). Immunosuppressive cells and stromal cells in the TME mutually promote the growth and maturation of OS cells (8).

The proliferation, angiogenesis, and apoptosis of OS cells are closely related to noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) (9, 10). miRNAs can regulate the proliferation and apoptosis of OS cells via their aberrant expression (11). Overexpression of mir-542-5p can enhance proliferation, but miRNA-1236-3p can decrease proliferation and promote apoptosis in OS cells (12, 13). lncRNAs can enhance OS progression, such as SNHG3, whose overexpression can speed up the migration and invasion of OS cells (14). circRNAs function as a miRNA sponge, regulating transcriptional or post-transcriptional gene expression and contributing to the control of OS incidence and development (15). lncRNA and circRNA can regulate the biological activity of OS cells by forming miRNA sponge, which act as competitive endogenous RNA (ceRNA) (10, 16). Studies on the metabolic properties of immunosuppressive cells and ncRNAs in OS cells promote the use of immunotherapy in the treatment of OS, including interferon treatments, checkpoint inhibitors, cancer vaccines, and engineered chimeric antigen receptor T (CAR-T) cells (4, 17). Among these, CAR-T cell treatment offers a significant advancement in T-cell-based immunotherapy and is predicted to be a game changer in OS immunotherapies (18). We summarize the metabolic properties of immunosuppressive cells in the TME and functional ncRNAs in OS in this paper. The targets, efficacy, and drug resistance of several recently developed immunotherapies are compared.

Noncoding RNAs in osteosarcoma

The pathophysiology of OS is related to aberrant oncogene activation and tumour suppressor gene inactivation induced by somatic mutations and epigenetic processes (19). Recent studies have increasingly focused on the dysregulation of ncRNAs, including miRNAs, lncRNAs, and circRNAs (9, 20).

MicroRNAs

miRNAs regulate cell proliferation, differentiation, apoptosis, and development by binding to the 3′ untranslated region (3′-UTR) of target miRNAs and are able to degrade or induce translational silencing in OS cells (21). miR-223-3p has been shown in studies to limit cadherin-6 expression by directly binding to the 3′-UTR of cadherin-6 and to inhibit the invasion, migration, growth, and proliferation of OS cells (22). The expression of miR-18b-5p, which is mediated by HIF-1α, is substantially increased in OS and is associated with a poor prognosis (23). In addition, miR-18b-5p promotes the incidence and development of OS by inhibiting the expression of the tumour suppressor gene PHF2 (23). miRNA-98-5p is under-expressed in OS and inhibits cell cycle progression and migration potential by down-regulating CDC25A, thereby inducing OS apoptosis (24). Overexpression of miRNA-1236-3p in HOS cells reduces proliferation, stops the cell cycle in the G0/G1 phase, and promotes apoptosis (13). A differential analysis of miRNA expression in OS (Figure 1A) shows that the expression of let-7A-2 and miR-323 is decreased, whereas the expression of miR-182 is increased, suggesting that miR-182 could be a possible therapeutic target in OS. The detailed information of differentially expressed ncRNAs in A-C is presented in Table S1.

Long noncoding RNAs

The expression of lncRNA MELTF-AS1 is significantly increased in OS and promotes OS metastasis by upregulating the expression of MMP14 (25). lncRNA ODRUL can act as a competitive endogenous RNA (ceRNA) sponge of miR-3182 and promotes the proliferation, migration, invasion, and tumour growth of OS by upregulating the expression of matrix metalloproteinase (MMP) II (26). The oncogenic
effects of LncRNA CBR3-AS1 are executed by regulating the network of the miR-140-5p/DDX54-NucKS1-mTOR signalling pathway, which encourages stemness and epithelial–mesenchymal transition (EMT) of OS (27). The overexpression of lncRNA EBLN3P promotes the progression of OS cells, which is indicative of the stimulating effects of EBLN3P (28). In OS cells, the expression of the lncRNAs ENSG00000233086.8 and ENSG00000269821 is much higher (Figure 1B). By examining the molecular pathways and regulatory mechanisms further, one may be able to control the development of OS.

Circular RNAs

circECE1 is highly expressed in OS tissues and cells, and its association with c-Myc promotes tumour proliferation and metastasis by boosting glucose metabolism in OS cells to prevent speckle-type POZ-mediated ubiquitination and degradation of c-Myc (29). C-Myc-targeting checkpoint inhibitors have been demonstrated to impede OS development via modulating the production of ncRNAs (30). Studies have shown that knockdown of circRNA circ_001422 significantly inhibits the proliferation and metastasis of OS cells and
promotes apoptosis. Regulating the miR-195-5p/FGF2/PI3K/AKT axis produces the opposite impact of overexpression (31). circMYO10 has been confirmed as a promoter of OS progression by regulating the miR-370-3p/RUVBL1 axis and chromatin remodelling, consequently boosting the transcriptional activity of the β-catenin/LEF1 complex (32). The number of circRNAs with decreased expression was much greater than those with enhanced expression (Figure 1C), a finding that could be leveraged to design targeted therapies once the regulatory mechanisms of these circRNAs have been elucidated.

Recent research has increasingly focused on the impacts and mechanisms of microRNAs, whereas research into lncRNAs and circRNAs is still in its infancy (Table 1) (102). More research points to the importance of noncoding RNAs in OS, both in terms of diagnosis and treatment (9). An alternative mechanism for OS chemotherapeutic resistance has been proposed through the construction of ceRNA networks, in which noncoding RNAs bind to mRNAs (103). Differential expression of noncoding RNAs and the formation of ceRNA networks may lead to the development of more effective treatment techniques and the ability to overcome drug resistance in OS (Figure S1).

**Immunosuppressive cells in osteosarcoma**

**Myeloid-derived suppressor cells**

Immature bone marrow cells (IMCs) differentiate into mature macrophages, dendritic cells, and granulocytes under physiological conditions and transform into immunosuppressive MDSCs when regulated by chemokines in the TME (104). MDSCs generate pro-inflammatory substances such as NO, IL-1, and IL-6, which expose OS cells to a persistently inflammatory environment and dramatically enhance the risk of DNA damage and tumour cell proliferation, which may contribute to the progression of OS (105, 106). Through the activation of the activator for transcription 3, miR-21 and IL-6 can synergistically enhance the development of MDSCs and influence treatment resistance (107). Reactive oxygen species (ROS) produced by oxidative stress can activate the NF-κB and Nrf2 pathways, allowing tumour cells to survive (108). MDSCs generate excessive ROS via NOX2 and suppress the antitumor effects of T cells and natural killer (NK) cells, hence mediating OS immune escape while maintaining oxidative balance via glycolysis upregulation (109, 110).

The TME alters the lipid metabolism of MDSCs to enhance the uptake of fatty acids and the activation of fatty acid oxidation (FAO), thereby improving the immunosuppressive activity of MDSCs and promoting tumour growth (110). In addition to LXR agonists, liver-X nuclear receptors (LXRs) regulate cholesterol and lipid metabolism via the transcription target Apolipoprotein E (111). LXR agonists have been demonstrated to play a role in MDSC depletion, which could be related to FAO inhibition in MDSCs (112). By increasing the activities of arginase-1, MDSCs compete with T cells for the consumption of arginine, which leads to T cell dysfunction (113). L-arginine supplementation may improve the anticancer impact of cyclophosphamide (CP) and minimize T cell dysfunction caused by increased MDSCs generated by CP (114).

**Tumour-associated macrophages**

TAMs are the primary immune cells in the TME, which are usually produced from bone marrow monocytes, and the presence of TAMs is indicative of a poor prognosis in OS patients (115, 116). TAMs, via stimulating the COX-2/STAT3 axis and causing epithelial–mesenchymal transition, can increase OS pulmonary metastasis (117). C-C motif chemokine ligand 18 secreted by TAMs has been shown to promote the proliferation and metastasis of OS cells via the EP300/UCA1/Wnt/β-catenin pathway, which significantly reduces the survival rate of OS patients (118). Studies have demonstrated that miR-363 inhibitors can promote the migration of TAMs after transfection of OS cells (119).

TAMS can be divided into classically activated macrophages (M1), with antitumor activity, and selectively activated macrophages (M2), with tumour-promoting activity, both of which can coexist in the TME (120). It has been found that M2 can promote the deterioration of OS cells through the SOCS3/JAK2/STAT3 axis, and OS cells can enhance the M2 polarisation of TAMs (121). LncRNA RP11-361F15.2 enhances M2 polarisation mediated by cytoplasmic polyadenylate element binding protein 4 through miR-30c-5p and further promotes the occurrence of OS (122).

TAMs substitute glycolysis with FAO as a source of energy by expressing a high amount of the scavenger receptor CD36, which enhances lipid accumulation and reprograms TAMs into M2 types (123). S100A4 has been reported in mice to upregulate FAO and mediate TAM polarization to M2, as well as to have carcinogenic activity (124).

**Treg cells**

Extensive Treg cell infiltration into tumour tissues is often associated with a poor prognosis, whereas their removal enhances antitumor immune responses (125). FOXP3+ expression in Treg cells has been shown to predict the prognosis of osteosarcoma in vivo and in vitro and could potentially be used as a diagnostic marker in clinical practice (126–128).
| Non-coding RNA | Expression | Function | Ref |
|----------------|------------|----------|-----|
| miR-873 | upregulate | Related to tumor size, clinical stage and distant metastasis in OS. | (33) |
| miR-23b-3p | upregulate | Inhibit OS cell proliferation. | (34) |
| miR-367 | upregulate | Inhibit the proliferation, migration and invasion of OS cells. | (35) |
| miR-21 | upregulate | Play a main role in proliferation, migration, invasion and apoptosis. | (36) |
| miR-107 | upregulate | Promoted U2OS cell viability, migration, and invasion whereas inhibit apoptosis. | (37) |
| miR-590-3p | downregulate | Inhibit proliferation and metastasis in OS cells. | (38) |
| miR-520a-3p | downregulate | Tumor suppressor. | (39) |
| miR-491 | downregulate | Stimulate OS cell lung metastasis and suppresses CDDP-induced tumor growth inhibition and apoptosis. | (40) |
| miR-449a | downregulate | Decrease cyclin A2 levels and inhibit proliferation rate, migratory potential, and colony-forming ability of OS cells. | (41) |
| miR-432-3p | downregulate | Regulate SA and IA by targeting PDGFB genes. | (42) |
| miR-425-3p | downregulate | Suppress OS cell proliferation, invasion and migration in vitro. | (43) |
| miR-424 | downregulate | Decrease cyclin A2 levels and inhibited proliferation rate, migratory potential, and colony-forming ability of OS cells. | (44) |
| miR-377 | downregulate | Inhibit tumor growth and reduce tumor size. | (45) |
| miR-363-3p | downregulate | Inhibit the proliferation, migration, and invasion of U2OS and MG63 cells. | (46) |
| miR-342-3p | downregulate | Inhibit the proliferation, migration, and invasion of OS cells. | (47) |
| miR-26a | downregulate | Suppression of OS cell viability and migration. | (48) |
| miR-223-3p | downregulate | Inhibit cell invasion, migration, growth, and proliferation. | (49) |
| miR211 | downregulate | Decrease cyclin A2 levels and inhibit proliferation rate, migratory potential, and colony-forming ability of OS cells. | (50) |
| miR-133b | downregulate | Attenuate cell proliferation and invasion. | (51) |
| miR-377 | downregulate | Inhibit tumor growth and reduce tumor size. | (52) |
| lncRNA MALAT1 | upregulate | Promote OS cell viability, invasion and migration. | (53) |
| lncRNA TP73-AS1 | upregulate | Suppress OS cells proliferation and invasion in vitro as well as tumor growth in vivo. | (54) |
| lncRNA HNF1A-ASI | upregulate | Inhibit cell proliferation and G1/S transition, and suppress migration and invasion in OS cells. | (55) |
| lncRNA-BO50642 | upregulate | Promote cell proliferation, induce colony formation and meanwhile inhibit cell apoptosis. | (56) |
| lncRNA ODRUL | upregulate | Inhibit OS cell proliferation, migration, invasion, and tumor growth in vitro and vivo. | (57) |
| lncRNA ITG82-ASI | upregulate | Inhibit the proliferation and induce apoptosis of OS cells. | (58) |
| lncRNA ANRIL | upregulate | Associate with increased rates of metastases at diagnosis and death. A significant predictor of reduced overall survival rate. | (59) |
| lncRNA XIST | upregulate | Responsible for OS cell proliferation and invasion. | (60) |
| lncRNA TUG1 | upregulate | Play an important role in the proliferation and metastasis of osteosarcoma. | (61) |
| lncRNA TUG1 | upregulate | Regulate OS cell metastasis, angiogenesis, and proliferation in vitro and vivo. | (62) |
| lncRNA TNK2-AS1 | upregulate | Inhibited proliferative, migratory, and invasive capacities while promoting apoptosis in OS cells. | (63) |
| lncRNA SNHG4 | upregulate | Suppress cell viability and invasion potential. | (64) |
| lncRNA SNHG3 | upregulate | Promote invasive and migratory potentials of OS cells. | (65) |
| lncRNA SNHG1 | upregulate | Inhibit cell growth and metastasis of OS in vitro and vivo. | (66) |
| lncRNA SNHG16 | upregulate | Contributes to the proliferation, migration and invasion of OS cells. | (67) |
| lncRNA OIP5-AS1 | upregulate | Increased doxorubicin resistance of OS cells. | (68) |
| lncRNA OIP5-AS1 | upregulate | Repress the proliferative ability and accelerated the apoptosis. | (69) |
| lncRNA MIR100HG | upregulate | Suppress cell proliferation, cell cycle progression while promote cell apoptosis. | (70) |
| lncRNA LINC01123 | upregulate | Promote cell progression. | (71) |
| lncRNA LINC00632 | upregulate | Accelerate the proliferation and migration of OS cells. | (72) |
| lncRNA KCNQ1OT1 | upregulate | Facilitate proliferation and suppressed apoptosis of OS cells. | (73) |
| lncRNA HULC | upregulate | Promote cell proliferation, migration and invasion and induce cell apoptosis. | (74) |
Glycolysis and oxidative phosphorylation, which are essential for Treg cell metabolism, require FAO (129). Treg cells in tumours, in contrast to normal tissues, have considerably decreased glucose uptake and are dysfunctional in a high-glucose environment (130). P13K inhibitors can reduce the immunosuppressive effects of Treg cells by upregulating glycolysis and reducing FOXP3 expression (131). miR-34a targets the 3’ UTR to inhibit the expression of FOXP3, which is controlled by the NF-κB pathway and downregulated by IL-6 and TNF-α (132). It has been demonstrated that the transcriptional regulator c-Myc influences oxidative phosphorylation in Tregs via regulating mitochondrial activity, hence limiting accumulation and functional activation (133). Targeting c-Myc and associated signalling pathways as a means of treating OS has drawn a lot of interest (29, 134).

Immunosuppressive cells can regulate the occurrence and development of OS through crosstalk with stromal cells in the TME (Figure 1D), which are regulated by ncRNAs in OS cells, according to the studies on the metabolic heterogeneity of immunosuppressive cells and the regulatory mechanisms of ncRNAs.

| Non-coding RNA | Expression | Function | Ref |
|---------------|------------|----------|-----|
| lncRNA HOXD-AS1 | upregulate | Suppress cell proliferation, colony formation, migration, and invasion, and promote cell cycle arrest at G1 stage and apoptosis in OS cells. | (73) |
| lncRNA HOXD-AS1 | upregulate | Inhibit the OS cells proliferation and induce G1/G0 phase arrest in vitro, and repress tumor cell growth in vivo. | (74) |
| lncRNA FOXD2-AS1 | upregulate | Repress the malignant biological properties of OS cells in vitro and vivo, including proliferation, invasion, apoptosis and tumor growth. | (75) |
| lncRNA DLEU1 | upregulate | Inhibit the cell proliferation, migration and invasion. | (76) |
| lncRNA DANCR | upregulate | Promote tumor growth and lung metastasis of OS. | (77) |
| lncRNA DANCNCR | upregulate | Increase OS cell proliferation, migration, and invasion. | (78) |
| lncRNA CCAT2 | upregulate | Promote OS cell proliferation, cell cycle and invasion. | (79) |
| lncRNA CRR3-AS1 | upregulate | Suppress OS cells proliferation, migration and invasion, and promote cells apoptosis. | (80) |
| lncRNA APTR | upregulate | Repress human OS cell proliferation, invasion and migration, and induce apoptosis. | (81) |
| lncRNA CAT104 | upregulate | Inhibit OS-732 cell proliferation, migration, and invasion, but promote cell apoptosis. | (82) |
| lncRNA LINC01128 | upregulate | Reduce the proliferation, migration and invasion of OS cells both. | (83) |
| lncRNA ZBTB7A | upregulate | Associate with OS metastasis. | (84) |
| lncRNA RSF1 | upregulate | Suppress OS cells proliferation and invasion. | (85) |
| lncRNA PUM2 | downregulate | Inhibit OS cells proliferation, migration, and stemness. | (86) |
| lncRNA XIST | downregulate | Inhibit the proliferation of OS cells. | (87) |
| lncRNA C2d4at1 | downregulate | Reduce cell viability, invasion, and migration, whereas increase cell apoptosis in OS-732 cells. | (88) |
| hsa_circ_0008934 | upregulate | Reduce proliferation, enhanced apoptosis, block cell cycle progression, and impair migration and invasion capacities of SAOS2 cells. | (89) |
| hsa_circ_0007534 | upregulate | Suppress OS cell growth. | (90) |
| circUSP34 | upregulate | Promote the proliferation, migration, and invasion of OS in vitro and vivo. | (91) |
| circ-LRP6 | upregulate | Inhibit the proliferation, migration and invasion of OS cells. | (92) |
| circUBAP2 | upregulate | Inhibit OS cell apoptosis. | (93) |
| circTADA2A | upregulate | Increase malignant tumor behavior. | (94) |
| hsa_circ_0002137 | upregulate | Suppress the progress of OS, including cell invasion, cell cycle and cell apoptosis. | (95) |
| circPVT1 | upregulate | Suppress OS tumor growth and metastasis in vitro. | (96) |
| circCEC1 | upregulate | Suppress tumor proliferation and metastasis both in vitro and vivo. | (97) |
| circ_0078767 | upregulate | Strengthen the proliferation, invasiveness, and migration of osteosarcoma cells. | (98) |
| circ_001621 | upregulate | Promote OS proliferation and migration. | (99) |
| circ_001422 | upregulate | Promote the proliferation and metastasis and inhibit the apoptosis of OS cells in vivo and vitro. | (100) |
| circ_0001721 | upregulate | Facilitates cell progression in OS. | (101) |
| circ_000658 | downregulate | Promote cell cycle, proliferation, invasion and migration but inhibit the apoptosis of OS cells. | (102) |
| circ_000190 | downregulate | Exhibit an obvious reduction in tissues of OS patients. | (103) |

**TABLE 1 Continued**
Immunotherapy in osteosarcoma

Interferon therapy

Interferon (IFN) is a cytokine that white blood cells generally secrete during infections (135). Due to its effects as an agonist of antitumor activity in adaptive and innate immune cells, it leads to the establishment of antiproliferative and antiangiogenic activity in osteosarcoma and antagonizes inhibitory immune subsets (135, 136). IFN-γ induces PKR-dependent autophagy in OS cells through signal transduction and activation of transcription 1, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase-dependent pathways (137). miR-142-5p enhances the transcription of IFN-γ by downregulating the expression of interaction protein domain 2 (138). miR-31 reduces interferon-γ production, thereby attenuating Th1 response (139). The efficiency of IFN therapy could be increased by modulating the aberrant expression of ncRNAs, which has a good synergy for drug development in the treatment of OS.

Checkpoint inhibitors

PD-1

In the tumour microenvironment of OS, PD-L1 on tumour cells interacts with PD-1 on T cells to inhibit T cell functional signalling, preventing the immune system from targeting tumour cells (140, 141). The antitumor activity of PD-1 can be aided by an SGLT2 inhibitor, and the synergistic effect stimulates the infiltration of CD4+ and CD8+ T lymphocytes into the OS tumour microenvironment (142). miR-140 was found to directly regulate the expression of PD-L1 by binding to its 3'-UTR, suggesting that it could be exploited as a new therapeutic drug targeting checkpoint inhibitors in OS (143). PBMC-loaded vMyx-hTNF may synergistically interact with the immune checkpoint inhibitor anti-PD-1, which has been reported in a mouse model of lung metastatic osteosarcoma (144).

C-Myc inhibitors

The ubiquitous dysregulation of the c-Myc oncogene in human malignancies makes it a promising therapeutic target (145). Recent research has demonstrated that c-Myc not only regulates cell proliferation, apoptosis, and cancer metabolism, but also the TME and immune responses (145). C-Myc inhibition reprograms the cancer immune milieu by attracting T lymphocytes and activating the CD40/CD40L system in OS, according to studies (30). miR-449c has been demonstrated to directly target and negatively inhibit the production of the oncogene c-Myc, hence encouraging the advancement of the OS cell cycle (146). Her4 can boost glucose intake and tumour growth by promoting OS metabolic reprogramming via a c-Myc-dependent signalling pathway, suggesting that a c-Myc inhibitor may be useful in the treatment of OS (147). The S1P/S1PR3 axis has been shown to contribute to the formation of the YAP-c-Myc complex and transcription of the glycolytic enzyme PGAM1 by suppressing YAP phosphorylation and increasing its nuclear translocation, according to studies (134).

SGLT2 inhibitors

Sodium–glucose cotransporter 2 (SGLT2) is essential for epithelial glucose transport and is overexpressed in numerous cancer types in order to supply cancer cells with glucose to satisfy their high-energy needs (148). SGLT2 affects the expression of miR-210 and stimulates anaerobic glycolysis, hence modulating the energy metabolism of cancer cells (149). SGLT2 inhibitors significantly inhibit osteosarcoma tumour growth and induce immune cell infiltration in vitro by upregulating STING expression and activating the IRF3/IFN-β pathway, which could be attributable to the inhibition of AKT phosphorylation (141).

Cancer vaccines

The protein EWS-FLI1, which is overexpressed in OS, has become a specific Treg antigen for vaccine development (150). EWS-FLI1 inhibits effector T cell responses and has been found circulating in or infiltrating tumours in Ewing patients, resulting in unfavourable clinical outcomes (150). Double sialic ganglioside (GD2) is extensively expressed in osteosarcoma (OS) and soft tissue sarcomas, and immunotherapies including GD2 vaccines have been utilized to treat solid tumor (151). miR-34a can target GD-2 to enhance tumour apoptosis, which is anticipated to be a novel OS target (152). Previous studies developed fusion cell vaccines by chemically fusing human γδT cells with SAOS-2 cells, eliciting cytotoxic T lymphocyte responses against two human OS cell lines that were specific to cancer antigens (153). CD103αcDC1 vaccines produced in vitro elicited systemic and long-lasting tumour-specific T cell-mediated cytotoxicity, thereby inhibiting the growth of primary and metastatic osteosarcoma (154).

Engineered chimeric antigen receptor T cells

Chimeric antigen receptor T cell therapy has been shown to be effective in leukaemia and lymphoma, and current studies have increasingly focused on CAR-T therapy for solid tumours, such as OS (155). The efficacy of B7-H3-CAR-T cell therapy in treating solid tumours was initially proven in a model of childhood cancer (156). Following that, the efficacy of B7-H3-CAR-T cells in OS and preventing lung metastasis progression was demonstrated in a dose-
dependent manner in a mouse model with orthotopic OS of the tibia and lung metastases (157). Human EpH2-directed CAR-T cells can target human OS cells in vitro, and the injection of CAR-T cells can eradicate tumour deposits in the liver and lungs of metastatic OS models in vivo (158). CD166 is selectively expressed in OS cells and can be used as a new target for CAR-T cell therapy, which has been demonstrated in mice models of OS by injection of CD166.BB CAR-T cells (159). Human epidermal growth factor receptor 2 (HER2)-CAR-T cells have entered phase II clinical trials, and the safety and efficacy of this therapy have been demonstrated in a study of 19 patients with HER2-positive solid tumours (160).

To treat OS, immunotherapy particularly targets immune cells and immunosuppressive cells in the TME. ncRNAs play a crucial regulatory role and have the potential to be exploited as synergistic agents for checkpoint inhibitors as well as novel targets for interferon treatments and cancer vaccines. The evidence of clinical data in interferon therapy and checkpoint inhibitors is shown in Table S2. CAR-T cells are a new therapeutic for solid tumours that can eradicate tumour cells from primary and metastatic lesions and may provide a unique immunotherapy treatment for patients with metastatic OS.

**Discussion**

The most frequent primary malignant tumour in children and adolescents is OS, which has a high rate of metastasis and a poor prognosis (161). A difference in the reduction in expression of let-7a-2 and miR-323 was identified in the differential analysis of ncRNAs in OS cells. let-7a-2 and miR-323 are regarded as sensitive prognostic indicators in a number of malignancies and may have a significant role in the clinical diagnosis of OS (162–164). The expression of circRNAs in OS is mainly decreased, of which circRNA_104892, circRNA_104893, and circRNA_104891 show significant differences in the degree of reduction. Reduced expression of circRNAs often inhibits osteosarcoma migration and invasion and promotes apoptosis, which could be combined with therapeutic targets for OS (165). IncRNA SNHG16 can function as ceRNA of miR-1285-3p to reduce the expression of miRNA, thus promote the proliferation, invasion and migration of OS cells (166). IncRNA regulates the progression of osteosarcoma through the miRNA axis, and there is no evidence for the direct regulation of IncRNA expression (167–170). IncRNA and circRNA can regulate the biological characteristics and metabolism reprogramming of OS by sponging miRNAs to represent as ceRNA (70, 94). The construction of co-expression networks of ncRNAs would be beneficial for studying OS aetiology.

OS immunotherapy primarily targets immunosuppressive cells in the TME, which are regulated by cytokines, chemokines, and an anaerobic environment (171). Gemcitabine effectively inhibited the progression of osteosarcoma by inducing cell apoptosis and inhibiting the accumulation of MDSCs (172). Additionally, when it binds to specific inhibitors of indoleamine 2, 3-dioxygenase, it can more effectively prevent the recruitment of MDSCs and the differentiation of Treg cells (172). The necessity to find novel targets has led to an increase in the number of studies on regulatory factors in OS cells. Meanwhile, when compared to a single inhibitor, a combination of inhibitors can greatly boost therapeutic efficacy. The energy uptake of immunosuppressive cells is more dependent on FAO and is also regulated by glucose levels in the TME (123, 130).

The development of combination chemotherapy has significantly increased the OS survival rate; however, the evolution of drug resistance has become a critical issue that must be addressed (173). Immunotherapy is a new strategy in the treatment of OS that targets immune cells to activate the immune system and relies on autoimmune responses to fight tumour tissues, an approach that may also be useful in combatting drug resistance (4, 173). Multiple types of checkpoint inhibitors have shown significant anticancer efficacy. The synergistic effects of checkpoint inhibitors and their combination with chemotherapy are promising options for combating drug resistance (4). Therapies based on OS-related antibodies have shown promise when combined with checkpoint inhibitors (154). In recent years, CAR-T cell treatment for OS has demonstrated encouraging results. (HER2)-CAR-T cells have entered phase II clinical trials and are expected to advance the treatment of OS (160).

In conclusion, this review summarizes the role of ncRNAs in OS cells, including their differential expression, as well as the metabolic heterogeneity of immunosuppressive cells in the TME. Emerging immunotherapies have been studied and compared in recent years, and their roles in the clinical diagnosis and treatment of OS have been investigated.

**Author contributions**

YX and DoW wrote the manuscript. YP, MC, DuW, ZJ and BL collected the references and prepared figures. All authors contributed to the article and approved the submitted version.

**Funding**

This research was financially supported by the National Natural Science Foundation of China (Grant Nos. 52022095, 82071391, 51973216, 51873207, and 51833010), the Provincial Health Special Project of Jilin Province (Grant Nos. JLSZD2019-002 and JLSWSRCZX2020–095), the Science and Technology Development Program of Jilin Province (Grant No. 20200404182YY), the Youth Innovation Promotion Association of Chinese Academy of Sciences (Grant No. 2019230), and Natural science Foundation of the Jilin province (Grant No. 20210101310JC), and Jilin Provincial Science and Technology Department Project (20220505033ZP).
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1025532/full#supplementary-material

Supplementary figure 1

The ceRNA network in OS cells.
33. Liu Y, Wang Y, Yang H, Zhao L, Song R, Tan H, et al. Microrna-873 Targets Hoxa9 to Inhibit the Aggressive Phenotype of Osteosarcoma by Deactivating the Wnt/Beta-Catenin Pathway. *Int J Oncol* (2019) 54(5):1809–20. doi: 10.3892/ijo.2019.4735

34. Zhu R, Li X, Ma Y. Mir-23b-3p Suppressing Pcgalp1 Promotes Proliferation through Reprogramming Metabolism in Osteosarcoma. *Cell Death Dis* (2019) 10:1036. doi: 10.1038/s41419-019-2164-4

35. Cai W, Jiang H, Yu Y, Xu Y, Zuo W, Wang S, et al. Mir-367 Regulation of Doc-2/Dab2 Interactive Protein Promotes Proliferation, Migration and Invasion of Osteosarcoma Cells. *BioMed Pharmacother* (2017) 95:1218–8. doi: 10.1016/j.biopha.2017.07.158

36. Sekar D, Mani P, Birunthu M, Sivagurunathan P, Karthikeyan M. Dissecting the Functional Role of Microrna in 21 in Osteosarcoma. *Cancer Gene Ther* (2019) 26(7–8):179–82. doi: 10.1042/14417-019-0092-x

37. Jiang R, Zhang C, Liu G, Gu R, Wu H. Microrna-107 Promotes Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting Trepomysin. *Int J Oncol* (2017) 53(8):1409–9. doi: 10.3736/s40064-017-4227-z

38. Wang WT, Qi Q, Zhao P, Li CY, Yin XY, Yan RB. Mir-590-3p Is a Novel Microrna Which Suppresses Osteosarcoma Progression by Targeting Sox9. *BioMed Pharmacother* (2018) 107:1756–9. doi: 10.1016/j.biopha.2018.06.124

39. Zhang B, Yu L, Han N, Hu Z, Wang S, Ding L, et al. Linc01116 Targets Mir-520a-3p and Affects lfe to Promote the Proliferation and Migration of Osteosarcoma Cells through the Jak-Stat Signaling Pathway. *BioMed Nanomater* (2018) 10:178–6. doi: 10.3390/bn8110016

40. Wang SN, Lu S, Liu C, Pao Z, Gou W, Wang Y, et al. Mir-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting Alphab-Crystallin. *Mol Ther* (2017) 25(9):2140–9. doi: 10.1038/mt.2017.0518

41. Sheikh R, Priyanka P, Kumar P, Ghosh T, Khan MM, Nagarajan P, et al. The Microrna Mir-146a and Mir-442 Suppress Osteosarcoma by Targeting Cdc42, Ap2 Expression. *J Biol Chem* (2019) 294(12):4801–400. doi: 10.1074/jbc.A118.003778

42. Vimalraj S, Subramanian R, Saravanan S, Arumugam B, Anuradha D. Microrna-432-5p Regulates Sprouting and Intussusive Angiogenesis in Osteosarcoma Microenvironment by Targeting Pdgfb. *Lab Invest* (2021) 101(8):1011–25. doi: 10.1038/s41374-021-00589-3

43. Yang G, Zhang C, Wang N, Chen J. Mir-425-2p Decreases Lncrna Malat1 and Tugi Expressions and Suppresses Tumorigenicity in Osteosarcoma Via Wnt/ Beta-Catenin Signaling Pathway. *Int J Biochem Cell Biol* (2019) 114:41–52. doi: 10.1016/j.biocel.2019.04.004

44. Xia P, Gu R, Zhang W, Shao L, Li F, Wu C, et al. Microrna-377 Exerts a Potent Suppressive Role in Osteosarcoma through the Involvement of the Histone Acetyltransferase 1-Mediated Wnt Ant. *Cell Physiol Biochem* (2019) 34(3):2278–98. doi: 10.1159/000492843

45. Wang K, Yan L, Fu F. Mir-363-3p Inhibits Osteosarcoma Cell Proliferation and Invasion Via Targeting Sox4. *Onco RNA* (2019) 27(2):157–63. doi: 10.3272/096054018X15190861873459

46. Zhang S, Liu L, Li Z, Li Q, Gong W, Wu H. Microrna-342-3p Inhibits the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting Astrocyte-Elevated Gene 1 (Aeg-1). *Onco RNA* (2017) 25(9):1505–15. doi: 10.3272/096054018X15190861873459

47. Wang J, Sun G, Foxol-Malat1-Mir-26a-5p Feedback Loop Mediates Proliferation and Migration in Osteosarcoma Cells. *Oncol Res* (2017) 25(19):1517–27. doi: 10.3272/096054018X1548845S417426

48. Pei Y, Yao Q, Li Y, Zhang X, Xie B. Microrna-211 Regulates Cell Proliferation, Apoptosis and Migration/Invasion in Human Osteosarcoma Via Targeting E朝廷. *Cell Mol Biol Lett* (2019) 24(4). doi: 10.11568/16150-019-0173-x

49. Ying S, Jianhui X, Xie Y, Shuwei L, Liyan S, Jie W, et al. Microrna-133b Inhibits Cell Proliferation and Invasion in Osteosarcoma by Targeting Sirt1. *Oncol Res* (2017) 25(9):1421–30. doi: 10.3272/096054018X14826809188085

50. Wang J, Pang W, Zuo Z, Zhang W, He W. Microrna-520b Suppresses Proliferation, Migration, and Invasion of Spinal Osteosarcoma Cells Via Downregulation of Fraz1. *Onco RNA* (2017) 25(8):1297–304. doi: 10.3272/096054018X148734834289189

51. Huang JH, Xu Y, Lin FY. The Inhibition of Microrna-326 by Sp1/Hdac1 Contributes to Proliferation and Metastasis of Osteosarcoma through Promoting Hif-1alpha Expression. *J Cell Mol Med* (2020) 24(18):9230–42. doi: 10.1111/jcmm.15176

52. Duan G, Zhang C, Xu C, Xu C, Zhang L, Zhang Y. Knockdown of Malat1 Inhibits Osteosarcoma Progression Via Regulating the Mir34a/Cyclin D1 Axis. *Int J Oncol* (2019) 54(1):17–28. doi: 10.3892/ijo.2018.4600

53. Yang G, Song R, Wang L, Wu X. Knockdown of Long Non-Coding Rna Tp7-3-As1 Inhibits Osteosarcoma Cell Proliferation and Invasion through Sponging Mir-142. *BioMed Pharmacother* (2019) 103:1228–45. doi: 10.1016/j.biopha.2018.04.146
Progression of Osteosarcoma through Regulating Mir-433-3p/Igf1r Axis.

Affecting Akt/Gsk-3beta Signaling Pathway.

Target Gene, Protects Osteosarcoma from Endoplasmic Reticulum Stress-Induced Aminoacyl-tRNA Synthetase 3A]

Effects: Dual Roles of Myeloid-Derived Suppressor Cells in Bone-Related Diseases.

Regulating Vegf Expression.

Affecting Interactions of Mfn1 and Tnc7 to Predict Competing Endogenous Rna Networks in Osteosarcoma Chemo-Resistance.

Regulon 21, 1 (2010): 510–515.

Transmitted Circular Rna Has_Circ_0000190 Suppresses Osteosarcoma Progression.

Macrophages Promote Lung Metastasis and Induce Epithelial-Mesenchymal Transition in Osteosarcoma-Associated Macrophages in Osteosarcoma Progression - Therapeutic Implications.

Osteosarcoma Cells Proliferation and Migration by Sponging Mir-578 and Regulating Vegf Expression.

Osteosarcoma Malignant Progression by Sponging Mir-16-5p.

Pharmacother 32(6):305. doi:10.1111/jon.12508

Prognosis and Promotes Tumorigenesis in Osteosarcoma.

Transition in Osteosarcoma by Activating the Cox-2/Stat3 Axis.

Macrophage Infiltration Predicts a Poor Prognosis for Human Ewing Sarcoma. Am J Pathol (2011) 179(3):1157–70. doi:10.1016/j.ajpath.2011.05.034

Effect of Anticancer Agents on Myeloid-Derived Suppressor Cells-an Overview of Combat Strategies to Increase Immunotherapy Efficacy.

Osteosarcoma Carcinogenesis Via Osteosarcoma Progression.

Effects: Dual Roles of Myeloid-Derived Suppressor Cells in Bone-Related Diseases.

CircRNA_induces_circ_0001721_Promotes_Osteosarcoma_Progression

Interactions of Mrnas and Ncrnas to Predict Competing Endogenous Rna Networks in Osteosarcoma Chemo-Resistance.

Tumor-Associated Macrophages in Osteosarcoma Progression - Therapeutic Implications.

CircRNA_Circ_0001721 Predicts Unfavorable Prognosis in Osteosarcoma and Facilitates Cell Progression Via Sponging Mir-569 and Mir-599. BioMed Pharmacother (2019) 109:226–32. doi:10.1016/j.biopha.2018.10.072

Zhang J, Chen D. Circular Rna_Hsa_Circ_0006568 Inhibits Osteosarcoma Cell Proliferation and Migration Via the Mir-127/Er2f Axis. J Cell Mol Med (2021) 25(1):510–20. doi:10.1111/jcm.16105

Li, S-P, Yang, T, Meng, W, Wu, X, Liu, C, Huang, J, Gao, Y. Circular Rna Cdr3-A1 Promotes Osteosarcoma Carcinogenesis Via Osteosarcoma Progression. BioMed Pharmacother (2018) 102:169–74. doi:10.1016/j.biopha.2018.02.081

Zhang L, Wang Y, Zhang L, Xia X, Chao Y, He R, et al. Zbtb7a, a Mir-663a Target Gene, Protects Osteosarcoma from Endoplasmic Reticulum Stress-Induced Apoptosis by Suppressing Lcrna Gas5 Expression. Cancer Lett (2019) 440-441:116–26. doi:10.1016/j.canlet.2021.06.009

Wang Y, Zeng X, Wang N, Zhao W, Zhang X, Feng S, et al. Long Noncoding Rna Dncr, Working as a Competitive Endogenous Rna, Promotes Rock1-Mediated Proliferation and Metastasis Via Decoying of Mir-335-5p and Mir-1972 in Osteosarcoma. Mol Cancer (2018) 17(1):89. doi:10.1186/s12935-018-0837-6

Jiang N, Wang X, Xie X, Liao Y, Liu N, Liu J, et al. Lncrna Dncr Promotes Tumor Progression and Cancer Stemness Features in Osteosarcoma by Upregulating Axl Via Mir-33a-5p Inhibition. Cancer Lett (2017) 405:46–55. doi:10.1016/j.cancert.2017.06.009

84. Zhang L, Wang Y, Zhang L, Xia X, Cao Y, Hu R, et al. Zbhb7a, a Mir-663a Target Gene, Protects Osteosarcoma from Endoplasmic Reticulum Stress-Induced Apoptosis by Suppressing Lncrna Gas5 Expression. Cancer Lett (2019) 440-441:116–26. doi:10.1016/j.canlet.2021.06.009

83. Wu D, Nie X, Ma C, Liu X, Liang X, Yang Y, et al. Rplf Functions as an Oncogene in Osteosarcoma and Is Regulated by Xist/Mir-193a-3p Axis. BioMed Pharmacother (2017) 95. Zhang M, Yu GY, Liu G, Liu WD. Circular Rna Hsa_Circ_0002137 Regulated the Progression of Osteosarcoma through Regulating Mir-433-3p/ Igrf1r Axis. J Cell Mol Med (2022) 26(6):1806–16. doi:10.1111/jcm.16166
161. Sangle NA, Layfeld LJ. Telangiectatic Osteosarcoma. Arch Pathol Lab Med (2012) 136(5):572-6. doi: 10.5858/arpa.2011-0204-RS

162. Wang BG, Jiang LY, Xu Q. A Comprehensive Evaluation for Polymorphisms in Let-7 Family in Cancer Risk and Prognosis: A System Review and Meta-Analysis. Biosci Rep (2018) 38(4). doi: 10.1042/BSR20180273

163. Liu Y, Li L, Liu Z, Yuan Q, Lu X. Plasma Mir-323 as a Biomarker for Screening Papillary Thyroid Cancer from Healthy Controls. Front Med (Lausanne) (2020) 7:122. doi: 10.3389/fmed.2020.00122

164. Jinkong S, Lin F, Yonghui L, Li Y, Weidong W. Identification of Let-7a-2-3p or/and Mir-188-5p as Prognostic Biomarkers in Cytogenetically Normal Acute Myeloid Leukemia. Plos One (2015) 10(2):e0118099. doi: 10.1371/journal.pone.0118099

165. Liu J, Yang L, Fu Q, Liu S. Emerging Roles and Potential Biological Value of Circrna in Osteosarcoma. Front Oncol (2020) 10:552236. doi: 10.3389/fonc.2020.552236

166. Xiao X, Jiang G, Zhang S, Hu S, Fan Y, Li G, et al. Lncrna Snhg16 Contributes to Osteosarcoma Progression by Acting as a Cerna of Mir-1285-3p. BMC Cancer (2021) 21(1):355. doi: 10.1186/s12885-021-07933-2

167. Fu D, Lu C, Qu X, Li P, Chen K, Shan L, et al. Lncrna Tin-Asl Regulates Osteosarcoma Cell Apoptosis and Drug Resistance Via the Mir-134-3p/Mbdi1 Axis. Aging (2019) 11(19):8374-85. doi: 10.18632/aging.102325

168. Han G, Guo Q, Ma N, Bi W, Xu M, Jia J, et al. Lncrna Bcril1 Facilitates Osteosarcoma Progression Via Regulating Mir-1303/Fgf7 Axis. Aging (Albany NY) (2021) 13(11):15501-10. doi: 10.18632/aging.203106

169. Zhao A, Liu W, Cui X, Wang N, Wang Y, Sun L, et al. Lncrna Tusc7 Inhibits Osteosarcoma Progression through the Mir181a/Rassf6 Axis. Int J Mol Med (2021) 47(2):563-94. doi: 10.3892/ijmm.2020.4825

170. Wang W, Li Y, Zhi S, Li J, Miao J, Ding Z, et al. Lncrna-Roe/Microrna-185-3p/Yap1 Axis Exerts Function in Biological Characteristics of Osteosarcoma Cells. Genomics (2021) 113(1 Pt 2):450-61. doi: 10.18632/aging.203106

171. Morales E, Olson M, Iglesias F, Daihya S, Luetkens T, Atanackovic D. Role of Immunotherapy in Ewing Sarcoma. J Immunother Cancer (2020) 8(2). doi: 10.1136/jitc-2020-000653

172. Fan Q, Zou J, Tian H, Huang C, Nize EC, Shi Z, et al. Nanoengineering a Metal-Organic Framework for Osteosarcoma Chemo-Immunotherapy by Modulating Indoleamine-2,3-Dioxygenase and Myeloid-Derived Suppressor Cells. J Exp Clin Cancer Res (2022) 41(1):162. doi: 10.1186/s13046-022-02372-8

173. Lilenthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int J Mol Sci (2020), 21(18). doi: 10.3390/ijms21186885